Notably, the decline in TXN2 expression among postmenopausal patients became more pronounced as MASLD advanced (Fig. 7d), underscoring the potential clinical importance of TRX2 monitoring in MASLD progression. The gene discussed is TXN2; the disease is metabolic dysfunction-associated steatotic liver disease.